Viking Therapeutics, Inc.VKTXNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+77.5%
5Y CAGR+55.9%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+77.5%/yr
vs +28.1%/yr prior
5Y CAGR
+55.9%/yr
Recent acceleration
Acceleration
+49.4pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
9.2x
Strong expansion
Streak
9 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $393.34M | +160.6% |
| 2024 | $150.92M | +49.7% |
| 2023 | $100.83M | +43.3% |
| 2022 | $70.36M | +26.4% |
| 2021 | $55.68M | +30.5% |
| 2020 | $42.66M | +31.6% |
| 2019 | $32.43M | +24.0% |
| 2018 | $26.16M | +37.2% |
| 2017 | $19.07M | +37.7% |
| 2016 | $13.85M | - |